Trial Profile
First-line chemotherapy combined with or without apatinib in patients with primary recurrence of cervical cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Aug 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
- Focus Therapeutic Use
- 23 Aug 2018 New trial record